ImmunoPrecise announces new results on silico epitope mapping application

ImmunoPrecise Antibodies (IPA) announces new benchmarking results that validate the accuracy and utility of its in silico epitope mapping application, part of the LENSai platform, with a direct comparison to gold-standard wet-lab methods. The results represent a notable advancement in computational biology, particularly in the field of antibody discovery, where high failure rates and costly, time-intensive experiments remain common industry challenges. LENSai’s AI-powered platform was able to match the performance of x-ray crystallography-the industry’s most precise but slowest and most expensive method-using sequence data alone.